标题
TMB or not TMB as a biomarker: That is the question
作者
关键词
TMB, Immune checkpoints, PD-L1
出版物
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 163, Issue -, Pages 103374
出版商
Elsevier BV
发表日期
2021-06-02
DOI
10.1016/j.critrevonc.2021.103374
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
- (2021) Cristina Valero et al. Nature Communications
- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
- (2021) Benoit Rousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
- (2021) G.L. Banna et al. ESMO Open
- Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy
- (2020) G. L. Banna et al. Clinical & Translational Oncology
- Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
- (2020) Mary A. Wood et al. Genome Medicine
- Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
- (2020) Giovanni Rossi et al. Cancers
- The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
- (2020) V. Prasad et al. ANNALS OF ONCOLOGY
- The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians
- (2020) V. Subbiah et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment
- (2020) Amblessed E. Onuma et al. GENE EXPRESSION
- KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
- (2020) D. Marinelli et al. ANNALS OF ONCOLOGY
- Promising predictors of checkpoint inhibitor response in NSCLC
- (2020) Friedlaender Alex et al. Expert Review of Anticancer Therapy
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer
- (2019) Pushpinder Kaur et al. Scientific Reports
- Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial
- (2019) Martin Reck et al. EUROPEAN JOURNAL OF CANCER
- Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
- (2019) Laura Fancello et al. Journal for ImmunoTherapy of Cancer
- Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
- (2019) Aaron M. Goodman et al. Cancer Immunology Research
- How liquid biopsies can change clinical practice in oncology
- (2019) G Siravegna et al. ANNALS OF ONCOLOGY
- Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers
- (2019) Hao-Xiang Wu et al. Annals of Translational Medicine
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature
- (2018) Katharina Schwarze et al. GENETICS IN MEDICINE
- Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
- (2018) Matteo Allegretti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
- (2018) Siddhartha Devarakonda et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Cancer Neoantigens
- (2018) Ton N. Schumacher et al. Annual Review of Immunology
- APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy
- (2018) Amélie Boichard et al. OncoImmunology
- Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens
- (2017) Judith N. Müller et al. Journal of Thoracic Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
- (2017) Michaela Kotrova et al. Molecular Diagnosis & Therapy
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations
- (2017) Amélie Boichard et al. OncoImmunology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
- (2016) R. M. Chabanon et al. CLINICAL CANCER RESEARCH
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
- (2016) Andrea Garofalo et al. Genome Medicine
- Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
- (2016) D. B. Johnson et al. Cancer Immunology Research
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- High-Throughput Sequencing Technologies
- (2015) Jason A. Reuter et al. MOLECULAR CELL
- Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
- (2015) Luís Felipe Campesato et al. Oncotarget
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis, Optimization and Verification of Illumina-Generated 16S rRNA Gene Amplicon Surveys
- (2014) Michael C. Nelson et al. PLoS One
- Integrated analysis of germline and somatic variants in ovarian cancer
- (2014) Krishna L. Kanchi et al. Nature Communications
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Assuring the quality of next-generation sequencing in clinical laboratory practice
- (2012) Amy S Gargis et al. NATURE BIOTECHNOLOGY
- Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform
- (2011) Martin Kircher et al. NUCLEIC ACIDS RESEARCH
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started